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Abstract
Isolates from patients with Clostridium difﬁcile infection (CDI) usually produce both toxin A (TcdA) and toxin B (TcdB), but an increasing
number of reports from Europe and Asia mention infections with TcdA-negative, TcdB-positive (A)/B+) strains, usually characterized as
PCR ribotype 017 (type 017). Incidence rates of CDI per 10 000 admissions in a 200-bed Argentinean general hospital were 37, 84, 67, 43,
48 and 42 for the years 2000 to 2005, respectively. The annual percentages of type 017 CDI were 7.7%, 64.6%, 91.4%, 92.0%, 75.0% and
86.4%, respectively. Comparison of 112 017-CDI patients with 41 non-017-CDI patients revealed that 017-CDI patients were more often
male (68.8% vs. 46.3%; odds ratio 2.55, 95% conﬁdence interval 1.23–5.50). All type 017 strains tested belonged to toxinotype VIII and had
a 1.8-kb deletion in tcdA. In addition, 90% of tested type 017 isolates had high-level resistance to clindamycin and erythromycin, determined
by the presence of the ermB gene. Multiple-locus variable-number tandem-repeat analysis (MLVA) was applied to 56 Argentinean isolates
and 15 isolates from seven other countries. Country-speciﬁc clonal complexes were found in each country. Among 56 Argentinean isolates,
four clonal complexes were recognized, accounting for 61% of all isolates. These clonal complexes did not show correlation over time, but
seemed to be restricted to speciﬁc wards, mainly internal medicine and pulmonology wards. A total of 56% of recurrent infections were
caused by a different isolate, despite identiﬁcation of an identical PCR-ribotype. We conclude that C. difﬁcile type 017 gradually replaced
other circulating PCR ribotypes and that MLVA provides detailed insight into nosocomial spread.
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Introduction
The spectrum of Clostridium difﬁcile-associated infection (CDI)
ranges from asymptomatic carriage to fulminant, relapsing
and potentially fatal colitis [1]. Pathogenic C. difﬁcile strains
release the toxins A (TcdA) and B (TcdB) that ultimately
mediate diarrhoea and colitis. The exact role of a third toxin
(binary toxin) is still unknown [2]. The initial consensus that
TcdA and TcdB act synergistically and that the action of TcdB
occurs via the tissue damage caused by TcdA resulted in the
view that TcdA was the most important factor for causing di-
arrhoeal disease [3]. However, since the discovery of TcdA-
negative, TcdB-positive (A)/B+) C. difﬁcile strains [4,5], at
least four outbreaks [6–9] caused by these strains have been
described and an increasing number of reports have men-
tioned clinical disease associated with these variants [10–13].
The percentage of A)/B+ strains among patients with CDI
has been described as approximately 3% in the UK and
France [14,15]. Recently, an increase in A)/B+ strains has
also been reported from Korea [16].
The most commonly found A)/B+ strain is PCR-ribotype
017, toxinotype VIII, serogoup F, and restriction enzyme anal-
ysis (REA) group CF [11]. This strain contains a 1.8-kb dele-
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tion in tcdA and a mutation at amino acid position 47, result-
ing in a stop codon and a truncated TcdA protein. Patients
infected with this strain show similar clinical presentation and
recurrence rates as patients infected with A+B+ strains [6,8].
Further subtyping can be performed by ampliﬁed fragment
length polymorphism (AFLP), REA and multiple-locus vari-
able-number tandem-repeat analysis (MLVA) [17–20]. MLVA
has also been applied as a highly discriminatory ﬁngerprinting
system to analyse clusters of C. difﬁcile infection cases caused
by epidemic ribotype 027 isolates [18,21].
This report describes a nearly total clonal replacement of
the heterogeneous population of C. difﬁcile by A)/B+ PCR
ribotype 017 (type 017) in an Argentinean hospital and com-
pares the clinical and demographic characteristics of patients
with CDI caused by type 017 (017-CDI) with those of non-
017-CDI patients. In addition, MLVA was applied to study
the spread of type 017 in more detail.
Materials and Methods
Study design
This study was performed from May 2000 to December
2005 in a 200-bed general hospital in Buenos Aires. During
this period, faecal samples from patients with clinically sus-
pected CDI were both cultured on selective media, after
alcohol pre-treatment, for the presence of C. difﬁcile [22]
and tested for the presence of C. difﬁcile toxins. Faecal sam-
ples were tested during the ﬁrst 2 years with an enzyme
immune assay (Cytoclone A/B; Meridian Diagnostics Inc.,
Cincinnati, OH, USA) and thereafter with a combined assay
for the detection of toxin A and cell wall antigen (Triage;
Biosite Diagnostics, Inc., San Diego, CA, USA). All isolates
were sent to the Anaerobe Reference Laboratory in Cardiff,
Wales (n = 40) and to Leiden University Medical Centre
(LUMC, n = 131) for further identiﬁcation.
Demographic and clinical data
Institutional board approval was obtained for the collection
of demographic patient data (age, gender), data on the wards
in which patients were diagnosed with CDI, and data on the
HIV status of patients and recurrence rates of CDI. A CDI
case was deﬁned as that of a patient with a positive labora-
tory assay for C. difﬁcile TcdA and/or TcdB in stools or a
toxin-producing C. difﬁcile organism detected in stool via cul-
ture [23]. A recurrent CDI case was deﬁned as an episode
that occurred within 8 weeks after the onset of the previous
episode [23]. Demographic and clinical data for patients with
type 017 were compared with equivalent data for patients
with other types. A Yates-corrected chi-square test was
used for the analysis of proportions. If a cell value was < 5
in the two-by-two table, Fisher’s exact test was used. Crude
relative risks were estimated as odds ratios (ORs) and
presented with a 95% conﬁdence interval (95% CI). All analy-
ses were performed using spss for Windows, Version 13.0
(SPSS, Inc., Chicago, IL, USA).
Reference strains
Fifteen known type 017 isolates from seven different coun-
tries were included and used as reference strains. These
strains have been characterized by MLVA and AFLP, as previ-
ously described [19,20].
Strain characterization
All isolates were genetically identiﬁed as C. difﬁcile using an
in-house PCR for the presence of the gluD gene, encoding
glutamate dehydrogenase (GDH), speciﬁc for C. difﬁcile [24].
All C. difﬁcile strains were further investigated by PCR ribo-
typing as described previously [25]. The presence of the
toxin genes tcdA and tcdB was investigated with standardized
techniques [26,27]. Toxinotyping was performed as
described by Rupnik et al. [28]. A random selection of
strains, distributed over the study period, was tested for
deletions in tcdC by PCR, using primers designed in-house
[24], and for the presence of binary toxin genes, as
described previously [29]. C. difﬁcile strains were also investi-
gated for the presence of the ermB gene, coding for resis-
tance to macrolides and lincosamides.
Multiple-locus variable-number tandem-repeat analysis
(MLVA)
A random selection of type 017 strains was tested by MLVA
using the seven markers, CdA6, CdB7, CdC6, CdG8, CdE7,
CdF3 and CdH9, as previously described, with one alter-
ation: a new reverse primer was developed for marker
CdG8: 5¢ ACCAAAAATTTCTAACCCAAC 3¢ [20]. The
genetic relationships among the genotypes were determined
by clustering them according to MLVA type using the num-
ber of differing loci and the summed absolute distance as
coefﬁcients for calculating the minimum spanning tree (MST),
as described by Marsh et al. [18], using the bionumerics soft-
ware (Version 4.6; Applied Maths NV, Sint-Martens-Latem,
Belgium). Brieﬂy, the summed absolute distance between
two MLVA-typed isolates is the summed tandem-repeat
difference (STRD) at all seven variable-number tandem-
repeat (VNTR) loci. Isolates with an STRD £ 10 were
deﬁned as genetically related, irrespective of the number of
differing loci. Clonal complexes were deﬁned by an STRD
£ 2, provided that isolates were single locus variants (SLVs)
or double locus variants (DLVs) of one another [18].
CMI Goorhuis et al. Clonal replacement by Clostridium difﬁcile PCR ribotype 017 1081
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1080–1086
Results
Incidence and strain characteristics
During the study period, 171 strains isolated from 153
patients were investigated; 131 were examined at LUMC and
40 were typed by author JSB in Cardiff, UK. Table 1 shows
annual rates of admissions, CDI incidence, toxinogenic cul-
tured isolates and type 017 isolates typed by MLVA. In total,
127 (74.3%) isolates were identiﬁed as type 017, 27 (15.8%)
as type 001, nine (5.3%) as type 012 and six (3.5%) as type
014. The remaining two strains were types 031 and 039.
All 131 isolates sent to Leiden were analysed in more
detail. Of these, 119 were identiﬁed as type 017, seven as
type 001, four as type 014 and one as type 039. The ermB
gene was present in 89.9% of type 017 strains, 85.8% of type
001 strains, 50% of type 014 strains and in the only type 039
strain. The percentage of ermB-positive strains showed an
upward trend for each year, from 67.9% in 2001 to 100% in
2005. All type 017 strains had the 1.8-kb deletion in tcdA
and contained tcdB. In total, nine type 017 strains were
investigated by toxinotyping (seven in 2001, one in 2002 and
one in 2003); all of these belonged to toxinotype VIII. In addi-
tion, none of these tested type 017 strains harboured binary
toxin genes or showed deletions in tcdC.
Epidemiological and demographic data
Of 153 CDI patients, 112 had 017-CDI and 41 had non-017-
CDI. Patients with 017-CDI were signiﬁcantly more often
male (68.8% vs. 46.3%; OR 2.55, 95% CI 1.23–5.30). No sig-
niﬁcant differences were found with regard to age, the ward
on which CDI was acquired, HIV status or recurrence rate
(9% and 12% for patients with 017-CDI and non-017-CDI,
respectively).
Thirteen of the 153 patients (8.5%) developed one or
more recurrences. In all patients with an initial type 017
infection (n = 8), this type was also identiﬁed in the recur-
rent episode(s). The other ﬁve patients had an initial infec-
tion with type 001. Among these, two had a recurrence with
type 001, one with type 012 and two with type 017. The
minimum time interval between the ﬁrst episode and recur-
rence with an identical type was 15 days and the average
interval was 26 days. The minimum interval between ﬁrst
episode and recurrence with a different type was 11 days
and the average interval was 21 days (not signiﬁcant).
MLVA was performed on a total of 71 isolates, including
56 Argentinean type 017 isolates and 15 type 017 isolates
from seven other countries. The Argentinean isolates were
derived from 45 patients and equally distributed over 2000–
2005. The VNTR loci CdC6, CdG8 and CdE7 were the most
variable, whereas the loci CdF3 and CdH9 were constant
and common to all 017 strains (with the exception of one
isolate for CdH9). In total, the 71 type 017 isolates could be
subtyped into 57 unique MLVA types.
Figure 1 shows the MST of all 71 typed isolates. Each
circle represents a unique MLVA type containing one or
more isolates. The dark grey circles represent one large
related cluster (dark grey cluster), deﬁned by an STRD £ 10,
containing 47 isolates. Within the dark grey cluster, ﬁve clo-
nal complexes (CC-A to CC-E) were identiﬁed, deﬁned by
an STRD £ 2. Of the 56 Argentinean isolates, 42 (75%)
belonged to the dark grey cluster. By contrast, ﬁve of the 15
(33%) reference strains belonged to this cluster. A total of
34 Argentinean isolates (61%) were located within clonal
complexes A–D, as was one reference strain (7%). Two
Argentinean clusters that were not related to the dark grey
cluster (light grey circles marked I and CC-1) were SLVs of
this cluster (STRDs of 16 and 25, respectively) and varied in
the same locus CdG8.
Among the reference strains, three clusters were identi-
ﬁed (light grey circles marked II and CC-2, and dark grey cir-
cles marked CC-E), all of which were country-speciﬁc. Of
the reference strains, 10 (67%) had a genetic distance of one
or multiple DLVs from the dark grey cluster, compared with
ﬁve (9%) of the Argentinean isolates.
To further elucidate the relatedness between the 56
Argentinean type 017 isolates, we considered the ward on
which CDI was diagnosed and the year of isolation in the
MST (Fig. 2). Clonal complexes were found among 20 (67%)
of 30 isolates from the internal medicine ward, nine (82%)
of 11 isolates from the pulmonology ward, four (50%) of
eight isolates from the intensive care unit, two (50%) of four
isolates from the surgical ward and one (33%) of three
isolates from other departments.
TABLE 1. Annual number of admissions, Clostridium difﬁcile
infection (CDI) incidence, number of cultured toxinogenic
isolates and number of type 017 isolates typed by multiple-
locus variable-number tandem-repeat analysis (MLVA)
Year
Number of
admissions
CDI
incidence
per 10 000
admissions
Number of
toxinogenic
culture-positive
isolates
Type 017
isolates typed
by MLVA (%)Total
Type
017 (%)
2000 3204* 37 13* 1 (7.7) 1 (100)
2001 4500 84 48 31 (64.6) 18 (58)
2002 4759 67 35 32 (91.4) 9 (28)
2003 5347 43 25 23 (92.0) 10 (43)
2004 4978 48 28 21 (75.0) 10 (47)
2005 5265 41 22 19 (86.4) 8 (42)
*Data from May 2000.
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The 56 Argentinean isolates were derived from 45
patients. Seven of these patients had one and one patient
had two recurrences of type 017. Table 2 presents the time
interval between episodes, number of differing loci and
STRD. Using the same deﬁnitions for clonality, four of nine
recurrences (44%) were caused by an identical isolate. Of
these, three differed only on locus CdC6 and one only on
locus CdG8. By contrast, ﬁve of nine recurrences (56%)
were caused by different isolates. Of these, one was an SLV
(STRD of 4) and differed only on locus CdE7. The other four
recurrences were DLVs (STRDs of 19, 24, 29 and 30,
respectively), of which three differed on loci CdE7 and
CdG8 and one differed on loci CdC6 and CdG8.
Discussion
During a period of 5 years, a clonal expansion of C. difﬁcile
PCR ribotype 017 was noticed, in which type 017 increas-
ingly replaced other types. In 2001, the incidence doubled,
from 37 to 84 per 10 000 admissions, after which it receded
to the previous endemic rate, approximating 40 per 10 000
admissions. The contribution of 017-CDI to the overall inci-
dence, however, remained very high. Clonal spread of type
017 has only been described in outbreak situations [6–8,30]
and this is the ﬁrst report of a persisting high incidence of
type 017 CDI in one hospital. The ﬁnding that signiﬁcantly
more male patients were affected by type 017 is of interest,
but no ﬁrm conclusions can be drawn as no information was
available on the male : female ratios of patients admitted to
the hospital and to speciﬁc wards. The recurrence rate for
type 017 (9%) was comparable with recurrence rates for
other PCR ribotypes (12%) and with the recurrence rates of
this strain described in outbreak situations [6,8].
Application of MLVA resulted in the recognition of 57
unique MLVA types among 71 type 017 isolates, encompass-
ing 56 Argentinean isolates and 15 isolates from other coun-
tries. When the isolates (n = 4) from a recurrent infection
FIG. 1. Minimum spanning tree analysis of 71 Clostridium difﬁcile isolates typed by multiple-locus variable-number tandem-repeat analysis (MLVA),
including 56 Argentinean isolates (Ar) and 15 isolates from other countries. Isolates are labelled by country plus a number. Unique isolates or
isolates with completely identical MLVA types are shown within a dark grey, light grey or white circle. The numbers between the circles repre-
sent the summed tandem repeat differences (STRDs) between MLVA types. All isolates in dark grey circles represent a large genetically related
cluster, deﬁned by an STRD £ 10. Within the light grey cluster, ﬁve boxed clonal complexes (CC-A to CC-E) are deﬁned by an STRD £ 2. Iso-
lates in light grey circles are genetically related clusters (clusters I and II in dashed boxes) or clonal complexes (CC-1 and CC-2) that do not
belong to the large dark grey cluster. The white circles represent isolates that are not related to light or dark grey isolates. Ned, the Nether-
lands; Pol, Poland; Jap, Japan; US, USA; Fr, France; Can, Canada.
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with an identical strain by MLVA were excluded from the
analysis, the structure of the spanning tree did not signiﬁ-
cantly change (data not shown). Argentinean isolates could
clearly be discriminated from isolates of other countries.
A total of 75% of the Argentinean isolates were genetically
related. Of the Argentinean isolates that were not related,
16% were SLVs and only 9% showed a greater genetic
distance. By contrast, 33% of the isolates from other coun-
tries were found in the related Argentinean cluster, whereas
67% were not related, all of which were double or triple
locus variants. In addition, all clonal complexes were coun-
try-speciﬁc (with the exception of one Canadian isolate in
CC-B). Among the Argentinean isolates, clonal complexes
did not show a correlation over time. Instead, these com-
plexes seemed to be restricted to speciﬁc wards, mainly
those for internal medicine and pulmonology, where 67%
and 82% of isolates, respectively, belonged to a clonal com-
plex. This observation suggests the continuous presence of
clones on these wards, providing a source for new infections
at various time intervals.
MLVA is a highly discriminatory typing method for C. difﬁ-
cile [18,20]. Killgore et al. [31] recently examined the
discriminatory power of seven DNA ﬁngerprinting tech-
niques when applied to 42 C. difﬁcile strains collected in four
countries. Only REA and MLVA had sufﬁcient power to dis-
tinguish strains from different outbreaks, and to discriminate
between North American and European type 027 isolates.
Recently, MLVA was compared with pulsed ﬁeld gel electro-
phoresis (PFGE) to determine its ability to identify C. difﬁcile
clusters among 91 type 027 isolates from nine hospitals in
the UK. MLVA was far superior to PFGE for analysing clus-
ters of CDI both within and between institutions [21].
The ﬁnding that a major proportion of recurrences is
caused by re-infection rather than relapse has been reported
before [32,33]. The difference here is that we found a major-
ity (56%) of recurrences that were caused by a different
FIG. 2. Minimum spanning tree of 56 Argentinean isolates, derived from Fig. 1, by ward and year. Isolates are labelled by department and the
last two digits of the year of isolation. Unique isolates or isolates with completely identical multiple-locus variable-number tandem-repeat analysis
(MLVA) types are shown within dark grey, light grey or white circles. The numbers between the circles represent the summed tandem repeat
differences (STRDs) between MLVA types. All isolates in dark grey circles represent a large genetically related cluster, deﬁned by an STRD £ 10.
Within the dark grey cluster, four boxed clonal complexes (CC-A to CC-D) are deﬁned by an STRD £ 2. Isolates in light grey circles are a
genetically related cluster (cluster I in a dashed box) and a clonal complex (CC-1) that do not belong to the large dark grey cluster. The white
circles represent isolates that are not related to light or dark grey isolates. IM, internal medicine; Pul, pulmonology; ICU, intensive care unit; Sur,
surgery; MC, medium care; EM, emergency medicine.
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strain, despite identiﬁcation of the identical PCR-ribotype in
initial infection and recurrence. This may be of clinical rele-
vance because the treatment approach towards a re-infection
with a different strain differs from the approach taken for
recurrent infections with the same strain. However, it
remains difﬁcult to distinguish between a re-infection with a
different strain and a relapse with the same endogenous
strain. The ﬁrst could represent a relapse with a different
previously unrecognized endogenous strain; the second could
represent a re-infection from the environment with the same
circulating strain. Van den Berg et al. [34] showed that differ-
ent PCR ribotypes could be found simultaneously in stool
samples of two of 23 patients with CDI. By contrast, O’Neill
et al. found that all 10 cultured colonies of each of 10
patients with a ﬁrst episode of CDI contained the same REA
type [32].
Important questions that arise from this report concern
how clinical replacement strain has established itself and per-
sisted. One explanation may reﬂect increased selection pres-
sure induced by antibiotic usage. Unfortunately, we were not
able to correlate CDI incidence rates with antibiotic usages
in daily deﬁned dosages in the different departments.
Another explanation may involve altered virulence properties
of type 017 isolates. All tested type 017 strains belonged to
toxinotype VIII, did not harbour binary toxin genes and con-
tained an intact tcdC, and 90% of type 017 isolates tested
harboured the ermB gene, coding for resistance to macro-
lides and lincosamides. Together, these observations are not
indicative of altered virulence characteristics, as observed for
PCR ribotype 027 strains.
It is very likely that, despite infection control measures,
spores of type 017 persisted in the hospital and were able to
cause continued transmission. This occurred especially in the
internal medicine and pulmonology wards. This persistence
may have been caused by contamination of the environment
or by ongoing spread through asymptomatic carriers, which
has recently been suggested as an important risk factor for
nosocomial transmission [35]. Our ﬁnding that 55% of recur-
rences were infections with a different 017 MLVA type sup-
ports the hypothesis that the environment and other
patients or healthcare workers contributed to the mode of
transmission signiﬁcantly.
We conclude that C. difﬁcile type 017 gradually replaced
other circulating PCR ribotypes and was associated with a
similar spectrum of clinical disease as that known for A+/B+
strains. Using MLVA, a more detailed insight into nosocomial
transmission of 017 isolates was obtained. Further research
is needed to understand the clonal spread and longterm epi-
demiology of type 017.
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